peptidesinstitute.org
HEALING

BPC-157

BPC-157 (Body Protection Compound 157)

Healing and Regenerative Peptide

Buy BPC-157
— authoritative voices whose published research informed this article

The information on this page is compiled from peer-reviewed research and is provided for educational and research purposes only. It is not medical advice, a diagnosis, or a treatment recommendation. Peptides discussed here may not be approved for human use in your jurisdiction. Always consult a qualified healthcare provider before starting, stopping, or modifying any health protocol.

Overview

What is BPC-157?

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide fragment derived from a protein isolated in human gastric juice. It was first identified and studied by Croatian researcher Predrag Sikiric and his team, who have published extensively on its cytoprotective and organoprotective properties.[1]

The peptide is notable for its exceptional oral and systemic stability relative to most peptides. In animal studies, BPC-157 has consistently demonstrated the ability to accelerate tendon healing through tendon outgrowth, cell survival, and cell migration.[2] It also appears to promote wound healing across multiple tissue types via angiogenesis and growth factor modulation.[3]

BPC-157 also shows profound effects on the gut-brain axis. Animal models show protection against NSAID-induced gut damage, promotion of intestinal anastomosis healing, and reversal of drug-induced dyskinesia and dopamine system disruption. These properties make it a subject of interest for inflammatory bowel conditions and neuroprotection research.

It is important to note that no peer-reviewed human clinical trial data currently exists for BPC-157. All evidence for its benefits in humans is extrapolated from animal research and anecdotal reports from the research community. The peptide is not FDA-approved and is classified as a research compound only.

Research Supply

Source high-purity BPC-157 for your research

Buy BPC-157
Protocol

Dosage Guide

Route: Subcutaneous or intramuscular injection; oral administration under investigation

Dosing Schedule

PeriodDose
Standard research dose200-400 mcg (0.2-0.4 mg) per day
Higher research dose500-1000 mcg (0.5-1.0 mg) per day
Divided dosingSplit into two injections of 100-250 mcg, AM and PM
Typical cycle length4-12 weeks on, 4 weeks off

Reconstitution

VIAL SIZE5 mg
WATER VOLUME2.5 mL
CONCENTRATION2 mg/mL (2000 mcg/mL)
Each 0.1 mL (10 units on a U-100 insulin syringe) = 200 mcg

Injection Volumes

DoseVolumeSyringe Units
200 mcg0.10 mL10 units
250 mcg0.125 mL12.5 units
400 mcg0.20 mL20 units
500 mcg0.25 mL25 units

Cycling Protocol

ON PERIOD

4-12 weeks of daily use

OFF PERIOD

4 weeks minimum off period

BPC-157 does not appear to cause hormonal suppression or significant receptor downregulation in animal studies, but research-use cycling protocols typically include off periods to allow assessment of baseline healing status and to reduce unknowns associated with prolonged use of an unstudied compound in humans.

Local vs. Systemic Injection

LOCAL INJECTION

Inject subcutaneously directly adjacent to the injured area (e.g., near a damaged tendon, joint capsule, or muscle belly). This is the preferred method for localized tissue injuries where direct tissue exposure is desired. Some researchers use intramuscular injection near the injury site for deeper tissue access.

SYSTEMIC INJECTION

Inject subcutaneously in the lower abdomen. This is the standard approach for gut-related applications (IBD, leaky gut, NSAID-induced damage), neurological effects, or when treating multiple sites simultaneously. Systemic delivery still appears effective for musculoskeletal healing based on animal studies.

Administration Tips

  • Use bacteriostatic water (not sterile water) for reconstitution to extend shelf life to 30 days refrigerated
  • For localized injury (tendon, muscle, joint): inject subcutaneously near the site of injury
  • For systemic effects (gut, brain, general healing): inject subcutaneously in the abdomen
  • Administer consistently at the same times each day for stable plasma levels
  • Store lyophilized (unmixed) vials at -20C for up to 24 months; at room temperature for up to 3 months
  • Store reconstituted solution refrigerated at 2-8C and use within 30 days
  • Use a 29-31 gauge insulin syringe; inject slowly to minimize site discomfort
Safety

Risks & Side Effects

Commonly Reported

Injection site redness or mild swellingNausea (less common than with GLP-1 agents)Dizziness or lightheadednessWarm or flushed sensation post-injectionVivid dreams (anecdotally reported)Temporary fatigue

Serious Risks

Unknown long-term effects

No human clinical trials exist. Long-term effects in humans are completely unknown. Use carries inherent unknown risk by definition.

Angiogenesis promotion

BPC-157 promotes new blood vessel formation. While beneficial for healing, this property theoretically raises concern in individuals with existing neoplastic (cancer) conditions, as new vasculature could support tumor growth.

Drug interactions

BPC-157 modulates dopamine, serotonin, and GABA systems in animal models. Interactions with psychotropic medications, opioids, and anticoagulants have not been formally studied in humans.

Immune modulation

Anti-inflammatory properties may mask symptoms of underlying infection or injury. Pain suppression could delay identification of serious conditions requiring medical intervention.

Related Research

Related Peptides

Expert Voices

Experts Covering BPC-157

Dr. William A. Seeds

MD -- Regenerative Medicine Pioneer

Dr. Andrew Huberman

PhD -- Stanford Neuroscientist

Jay Campbell

Health Optimization Author and Peptide Advocate

Dr. Ian W. Hamley

Diamond Professor of Physical Chemistry -- University of Reading

Matthew Farrahi

Biohacker, CEO of Sigma Compounds, and Fitness Creator

LEGAL DISCLAIMER

The information provided on this page is for educational and informational purposes only and is not intended as medical advice. BPC-157 is a research compound that has not been approved by the FDA or any regulatory authority for human use. No human clinical trial data exists for this compound. All referenced benefits are derived from animal studies and should not be interpreted as proven human effects. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.

Frequently Asked Questions

What is BPC-157?
BPC-157 is a synthetic peptide of 15 amino acids derived from a protective protein found in human gastric juice. Researchers study it for potential regenerative effects on tendons, ligaments, muscles, and the gastrointestinal tract. It remains a research compound without FDA approval for human use. All evidence comes from animal studies.
How does BPC-157 work?
BPC-157 appears to work through multiple mechanisms: upregulation of growth hormone receptors in damaged tissue, promotion of angiogenesis through nitric oxide and VEGF pathways, modulation of the FAK-paxillin signaling pathway involved in tissue repair, and interaction with dopamine, serotonin, and GABA neurotransmitter systems in animal models.
What does BPC-157 do for tendons and muscles?
In animal studies, BPC-157 accelerates tendon-to-bone healing, reduces recovery time after muscle tears, and promotes ligament repair.[2] It is thought to achieve this partly by increasing the density of growth hormone receptors at injury sites and by stimulating new blood vessel formation to improve nutrient delivery to damaged tissue.
What are BPC-157 side effects?
Reported side effects in the research and anecdotal community include injection site redness, mild nausea, dizziness, and temporary fatigue. More serious theoretical concerns include promotion of angiogenesis in individuals with existing cancer and unknown drug interactions with psychotropic medications or anticoagulants. No human clinical trial safety data exists.
What is the BPC-157 dosage for research purposes?
Research dosing protocols typically range from 200 to 400 mcg per day, often divided into two injections. Higher doses of 500 to 1000 mcg daily are also documented. For localized injury, injection near the site is common; for systemic effects, subcutaneous abdominal injection is standard. Typical cycles run 4 to 12 weeks.
Can BPC-157 be taken orally?
Oral administration of BPC-157 is under investigation. Unlike most peptides, BPC-157 demonstrates unusual stability in gastric acid, making oral delivery plausible for gut-related applications. However, oral bioavailability for systemic or musculoskeletal effects is not well established. Injectable forms are more commonly used in research protocols.
Is BPC-157 legal?
BPC-157 is not FDA-approved and is classified as a research compound. It is not a controlled substance in the United States, meaning possession is not a criminal offense, but it is not legal for human use. The regulatory status varies by country. Researchers and individuals use it at their own risk outside any clinical framework.
How long does it take BPC-157 to work?
Anecdotal reports from the research community describe noticeable changes in injury recovery within one to two weeks of consistent use. Animal studies show measurable tissue repair markers within days.[2] The timeline depends heavily on the injury type, dose, administration method, and individual biology. No human clinical data confirms a defined onset period.

References

  1. Sikiric P, Hahm KB, Blagaic AB, et al.. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut and Liver. 2020. PMID 31158953
  2. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH.. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology (1985). 2011. PMID 21030672
  3. Seiwerth S, Milavic M, Vukojevic J, et al.. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. 2021. PMID 34267654

Regulatory & Official Sources